# Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

> **NCT06640166** · PHASE2 · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Carcinoma
- Colorectal Neoplasms
- Colorectal Tumor
- Colorectal Adenocarcinoma
- Colorectal Cancer (CRC)
- Colorectal Cancer
- Colon Cancer
- Colon Adenocarcinoma
- Colon Carcinoma
- Colon Neoplasm

## Interventions

- **DRUG:** encorafenib + cetuximab + FOLFIRI

## Key facts

- **NCT ID:** NCT06640166
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640166, "Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06640166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*